Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights
01:23pm, Monday, 13'th Apr 2020
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced preliminary unaudited revenue for UDENYCA® and net income for the quarter ended March 31, 2020. Coherus
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights
01:22pm, Monday, 13'th Apr 2020
COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020
Sharp drop in chemo use negative for Amgen and Coherus, says Citi AMGN;CHRS
10:39am, Monday, 13'th Apr 2020
Sharp drop in chemo use negative for Amgen and Coherus, says Citi Citi AMGN CHRS
Coherus Biosciences (NASDAQ:CHRS) Rating Lowered to Sell at BidaskClub
06:42am, Saturday, 11'th Apr 2020
BidaskClub cut shares of Coherus Biosciences (NASDAQ:CHRS) from a hold rating to a sell rating in a research report released on Tuesday morning, BidAskClub reports. Other analysts have also issued res
Jane Street Group LLC Has $228,000 Holdings in Coherus Biosciences Inc (NASDAQ:CHRS)
10:46am, Friday, 10'th Apr 2020
Jane Street Group LLC increased its position in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 15.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and
AQR Capital Management LLC Purchases 19,254 Shares of Coherus Biosciences Inc (NASDAQ:CHRS)
08:32am, Friday, 10'th Apr 2020
AQR Capital Management LLC boosted its position in Coherus Biosciences Inc (NASDAQ:CHRS) by 107.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (
Prosecutors Close Inquiry Into Agribusiness’s Customs Payments
09:47pm, Wednesday, 08'th Apr 2020
CHS said the Justice Department notified the company in a February letter that the agency was closing its inquiry into the matter without taking action.
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
10:59am, Tuesday, 07'th Apr 2020
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
10:59am, Tuesday, 07'th Apr 2020
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Cubist Systematic Strategies LLC Has $818,000 Stock Position in Coherus Biosciences Inc (NASDAQ:CHRS)
09:24am, Tuesday, 07'th Apr 2020
Cubist Systematic Strategies LLC raised its position in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 63.2% in the 4th quarter, according to the company in its most recent Form 13F filing with th
Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
05:46pm, Monday, 06'th Apr 2020
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Assembly Biosciences (ASMB), with a price target of $30.00. The
Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
05:46pm, Monday, 06'th Apr 2020
In a report released today,
Salim Syed
from Mizuho Securities maintained a
Buy
rating on Assembly Biosciences (
ASMB
–
Research Report
), with a price target of
$30.00
. The company’s shares close
Victory Capital Management Inc. Acquires 1,541 Shares of Coherus Biosciences Inc (NASDAQ:CHRS)
11:18am, Monday, 06'th Apr 2020
Victory Capital Management Inc. increased its position in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 15.6% during the 4th quarter, according to its most recent filing with the Securities and E
